Genmab A/S income statement GNMSF

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, Genmab A/S reported revenue of $3.7 billion. Net income was $963.0 million, a profit margin of 25.9%. Operating income came to $1.1 billion, an operating margin of 28.6%. Diluted earnings per share were $15.37.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2025
Dec 31, 2025
Revenue
3,720
Cost of revenue
238
Gross profit
3,482
Research and development
1,606
Selling, general and administrative
626
Operating income
1,065
Pretax income
1,204
Income tax
241
Net income
963
Basic EPS
15.50
Diluted EPS
15.37
Weighted average shares, basic
65
Weighted average shares, diluted
63
Other measures
Interest coverage
3.96x
Margins
Gross margin
93.60%
Operating margin
28.63%
Pretax margin
32.37%
Profit margin
25.89%
Effective tax rate
20.02%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
GMAB (Nasdaq), GNMSF (OTC)
Headquarters
1253 Copenhagen K, Denmark
SEC filer status
Large accelerated filer
SEC CIK
1434265

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.